https://ts2.tech/en/why-cogent-biosciences-stock-is-down-today-after-its-fda-filing-for-bezuclastinib/
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib
Apr 13, 2026 - Cogent Biosciences shares fell 2.7% to $36.88 Tuesday after the company submitted a New Drug Application to the FDA for bezuclastinib in nonadvanced systemic
is downcogentbiosciencesstocktoday